OBJECTIVES: To identify and evaluate the feasibility of using real world data sources in Alzheimer’s disease in Europe for the purpose of supporting future pharmacoeconomics or outcomes research. METHODS: A systematic literature search using MEDLINE and EMBASE databases was performed to identify published observational studies in Alzheimer’s disease or dementia within Europe since 2000. Data sources were identified from these studies and included in the evaluation if clinical outcomes data were collected. Details of the data source, patient and disease information (demographics, diagnosis, disease severity, treatment, comorbidities, quality of life), resource utilisation, caregiver burden, and potential for additional analyses to be conducted, were extracted for evaluation. The data collected was verified with the data holder where possible. RESULTS: The search retrieved 3742 records, of which 136 were eligible for inclusion following screening. From these a total of 37 data sources were identified and included for evaluation, with patients from several European countries (6), Denmark (2), Finland (2), France (7), Germany (2), Italy (3), Netherlands (4), Norway (1), Spain (4), Sweden (3), and United Kingdom (3). Most were prospective observational studies, typically with patients followed at 6-monthly intervals for up to 4 years. Almost all data sources collected demographics, disease, and treatment information, 17 (46%) also collected resource utilization, 21 (57%) had records of caregiver burden, and 7 (19%) were known to have patient quality of life information. Three data sources deemed to be most comprehensive against the criteria and accessible to external researchers (via the European Alzheimer’s disease Consortium) were ICTUS (pan-EU, 1,381 patients), REAL (France, 683 patients), and ALFINE (France, 112 patients). CONCLUSIONS: Three accessible European Alzheimer’s disease data sources were identified with the potential to support future pharmacoeconomics and outcomes research. The ICTUS study was found to provide the most comprehensive patient population and range of data collected.